Arabinogalactan protein from Arachis hypogaea: Role as carrier in drug-formulations

International Journal of Pharmaceutics

Volumn 333, Issue 1-2, 2007, Pages 79-86

  Parveen, Seema ^a   Gupta, Ashish D ^a   Prasad, Ramasare ^a  

^a INDIAN INSTITUTE OF TECHNOLOGY ROORKEE   (India)

Author keywords

Amphotericin B; Arabinogalactan protein; Candida albicans; Yariv reagent

Indexed keywords

AMPHOTERICIN B; ARABINOGALACTAN; DRUG CARRIER; SCHIFF BASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA ALBICANS; CONTROLLED STUDY; DRUG CONJUGATION; DRUG FORMULATION; DRUG STRUCTURE; MALE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PEANUT; PRECIPITATION; PRIORITY JOURNAL; PROTEIN ISOLATION; PROTEIN PURIFICATION;

AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; ARACHIS HYPOGAEA; CANDIDA ALBICANS; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; HEMOLYSIS; MALE; MAXIMUM TOLERATED DOSE; MICE; MICE, INBRED BALB C; MICROBIAL SENSITIVITY TESTS; MUCOPROTEINS; PLANT PROTEINS; SHEEP; SOLUBILITY; WATER;

EID: 33847130494     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2006.10.003     Document Type: Article

References (47)

1. Adler-Moore J., and Proffitt R.T. AmBisome: liposomal formulation, structure, mechanism of action and pre-clinical experience. J. Antimicrob. Chemother. 49 (2002) 21-30
2. Baginski M., Resat H., and Borowski E. Comparative molecular dynamics simulations of amphotericin B-cholesterol/ergosterol membrane channels. Biochim. Biophys. Acta 1567 (2002) 63-78
3. Balakrishan A.R., and Easwaran K.R. CD and NMR studies on the aggregation of amphotericin B in solution. Biochim. Biophys. Acta 1148 (1993) 269-277
4. Barrett J.P., Vardulaki K.A., Conlon C., Cooke J., Daza-Ramirez P., Evans E.G., Hawkey P.M., Herbrecht R., Marks D.I., Moraleda J.M., Park G.R., Senn S.J., and Viscoli C. A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations. Clin. Ther. 25 (2003) 1295-1320
5. Barwicz J., and Tancrede P. The effect of aggregation state of amphotericin-B on its interactions with cholesterol- or ergosterol-containing phosphatidylcholine monolayers. Chem. Phys. Lipids 85 (1997) 145-155
6. Bodey G.P. Infectious complications in cancer patient. Curr. Probl. Cancer 1 (1977) 1-63
7. Brajtburg J., and Bolard J. Carrier effects on biological activities of amphotericin B. Clin. Microbiol. Rev. 9 (1996) 512-531
8. In: Budavari S.O., Neil M.J., Smith A., and Heckelman P.E. (Eds). The Merck Index: An Encyclopedia of Chemicals, Drugs, and Biologicals (1989), Merck & Co., New York 93
9. Charvalos E., Manolis N.T., Van Bambeke F., Tulkens P.M., Aristidis M.T., George N.T., and Marie-Poule M.L. Water soluble amphotericin-B-polyvinylpyrrolidone complexes with maintained antifungal activity against Candida spp. and Aspergillus spp. and reduced haemolytic and cytotoxic effects. J. Antimicrob. Chemother. 57 (2006) 236-244
10. Classen B., Witthohn K., and Blaschek W. Characterization of an arabinogalactan protein isolated from pressed juice of Echinacea purpurea by precipitation with the β-Glucosyl Yariv reagent. Carbohydr. Res. 327 (2000) 497-504
11. Cleary J.D., Rogers P.D., and Chapman S.W. Variability in polyene content and cellular toxicity among deoxycholate amphotericin B formulations. Pharmacotherapy 23 (2003) 572-578
12. Clemons K.V., and Stevens D.A. Comparative efficacies of four amphotericin B formulations-Fungizone, amphotec (Amphocil), AmBisome, and Abelcet against systemic murine aspergillosis. Antimicrob. Agents Chemother. 48 (2004) 1047-1050
13. Conover C.D., Zhao H., Longley C.B., Shum K.L., and Greenwald R.B. Utility of poly(ethylene glycol) conjugation to create prodrugs of amphotericin-B. Bioconjug. Chem. 14 (2003) 661-666
14. Denning D.W. Epidemiology and pathogenesis of systemic fungal infections in the immunocompromised host. J. Antimicrob. Chemother. 28 (1991) 1-16
15. Domb A.J., Linden G., Polacheck I., and Benita S. Nystatin-dextran conjugates: synthesis and characterization. J. Polymer Sci. 34 (1996) 1229-1236
16. Donnelly J.P., and De Pauw B.E. Voriconazole-a new therapeutic agent with an extended spectrum of antifungal activity. Clin. Microbiol. Infect. 10 (2004) 107-117
17. Egert D., and Beuscher N. Studies on antigen specificity of immunoreactive arabinogalactan proteins extracted from Baptisia tinctoria and Echinacea purpurea. Planta Med. 58 (1992) 163-165
18. Ehrenfreund-Kleinman T., Azzam T., Falk R., Polacheck I., Golenser J., and Domb A.J. Synthesis and characterization of novel water soluble amphotericin B-arabinogalactan conjugates. Biomaterials 23 (2002) 1327-1335
19. Ernst C., Grange J., Rinnert H., Dupont G., and Lematre J. Structure of amphotericin-B aggregates as revealed by UV and CD spectroscopies. Biopolymers 20 (1981) 1575-1583
20. Falk R., Domb A.J., and Polacheck I. A novel water-soluble Amphotericin B arabinogalactan conjugate. Antimicrob. Agents Chemother. 43 (1999) 1975-1981
21. Folk R., Jacob G., Hoffmann A., Abraham J.D., and Polacheck I. Distribution of Amphoptericin B-Arabinogalactan conjugate in mouse tissue and its therapeutic efficacy against murine aspergillosis. Antimicrob. Agents Chemother. 48 (2004) 3006-3009
22. Foster D., Washington C., and Davis S.S. Toxicity of solubilized, and colloidal amphotericin B formulation to human erythrocyte. J. Pharm. Pharmacol. 40 (1988) 325-328
23. Gallis H.A., Drew R.H., and Pickard W.W. Amphotericin B: 30 years of clinical experience. Rev. Infect. Dis. 12 (1990) 308-329
24. Gasper Y., Johanson K.L., McKenna J.A., Bacic A., and Schultz C.J. The complex structure of arabinogalactan proteins and the journey towards understanding function. Plant Mol. Biol. 47 (2001) 161-176
25. Groll A.H., and Walsh T.J. Uncommon opportunistic fungi: new nosocomial threats. Clin. Microbiol. Infect. 7 (2001) 8-24
26. Harbarth S., Burke J.P., Lloyd J.F., Evans R.S., Pestotnik S.L., and Samore M.H. Clinical and economic outcomes of conventional amphotericin B associated nephrotoxicity. Clin. Infect. Dis. 35 (2002) e120-e127
27. Hartsel S., and Bolard J. Amphotericin B: new life for an old drug. Trends Pharmacol. Sci. 17 (1996) 445-449
28. Hauer J., and Anderer F.A. Mechanism of stimulation of human natural killer cytotoxicity by arabinogalactan from Larix occidentalis. Cancer Immunol. Immunother. 36 (1993) 237-244
29. Huang W., Zhang Z., Han X., Tang J., Wang J., Dong S., and Wang E. Ion channel behavior of amphotericin B in sterol free and cholesterol or ergosterol containing supported phosphatidylcholine bilayer model membranes investigated by electrochemistry and spectroscopy. Biophys. J. 83 (2002) 3245-3255
30. Johnson M.D., and Perfect J.R. Caspofungin: first approved agent in a new class of antifungals. Expert Opin. Pharmacother. 4 (2003) 807-823
31. Kelly G.S. Larch arabinogalactan: clinical relevance of a novel immune-enhancing polysaccharide. Altern. Med. Rev. 4 (1999) 96-103
32. Kobayashi G.S., Little J.R., and Medoff G. In vitro and in vivo comparisons of amphotericin B and N-d-ornithyl amphotericin B methyl ester. Antimicrob. Agents Chemother. 27 (1985) 302-305
33. Lamy-Freund M.T., Ferreira V.F.N., Alario A.F., and Schreier S.E. Effect of aggregation on the kinetics of autoxidation of the polyene antibiotic amphotericin B. J. Pharm. Sci. 82 (1993) 162-166
34. Lewis R.E., and Wiederhold N.P. The solubility ceiling: a rationale for continuous infusion amphotericin B therapy?. Clin. Infect. Dis. 37 (2003) 871-872
35. Maddux M.S., and Barriere S.L. Review of complication of amphotericin B therapy: recommendation for prevention and management. Drug Intell. Clin. Pharm. 14 (1980) 177-181
36. Manosroi A., Kongkaneramit L., and Manosroi J. Stability and transdermal absorption of topical amphotericin B liposome formulations. Int. J. Pharm. 270 (2004) 279-286
37. Moreno M.A., Frutos P., and Ballesteros M.P. Lyophilized lecithin based oil-water microemulsions as a new and low toxic delivery system for amphotericin B. Pharm. Res. 18 (2001) 344-351
38. Ostrosky-Zeichner L., Rex J.H., Pappas P.G., Hamill R.J., Larsen R.A., Horowitz H.W., Powderly W.G., Hyslop N., Kauffman C.A., Cleary J., Mangino J.E., and Lee J. Antifungal susceptibility survey of 2000 blood stream Candida isolates in the United States. Antimicrob. Agents Chemother. 47 (2003) 3149-3154
39. Razzaque M.S., Hossain M.A., Ahsan N., and Taguchi T. Lipid formulations of polyene antifungal drugs and attenuation of associated nephrotoxicity. Nephron 89 (2001) 251-254
40. Sabra R., and Branch R.A. Amphotericin B nephrotoxicity. Drug Saf. 5 (1990) 94-108
41. Schultz C.J., Johnson K.L., Currie G., and Bacic A. The classical arabinogalactan protein gene family of arabidopsis. Plant Cell 12 (2000) 1751-1768
42. Showalter A.M. Arabinogalactan-proteins: structure, expression and function. Cell. Mol. Life Sci. 58 (2001) 1399-1417
43. Singh N. Changing spectrum of invasive candidiasis and its therapeutic implications. Clin. Microbiol. Infect. 7 (2001) 1-7
44. Straus G., and Kral H. Borate complxes of amphotericin-B: polymeric species and aggregates in aqueous solutions. Biopolymers 21 (1982) 459-470
45. Szlinder-Richert J., Cybulska B., Grzybowska J., Bolard J., and Borowski E. Interaction of amphotericin B and its low toxic derivative, N-methyl-N-d-fructosyl amphotericin B methyl ester, with fungal, mammalian and bacterial cells measured by the energy transfer method. Farmaco 59 (2004) 289-296
46. Yu B.G., Okano T., Kataoka K., and Kwon G. Polymeric micelles for drug delivery: solubilization and haemolytic activity of amphotericin B. J. Control. Release 53 (1998) 131-136
47. Yu K.W., Kiyohara H., Matsumoto T., Yang H.C., and Yamada H. Intestinal immune system modulating polysaccharides from rhizomes of Atractylodes lancea. Planta Med. 64 (1998) 714-719